The efficiency of our method was evaluated for the preparations of monoclonal antibodies, blood plasma of mice immunized with the recombinant S-protein fragment RBD [21], Sputnik V (Gamaleya NRCEM) [22,23], and CoviVac (Chumakov FSC R&D IBP RAS) [24] vaccines, as well as of COVID-19-infected patients vaccinated with Sputnik V and CoviVac. Here, PROS1 is linked to COVID-19.